VERTEX PHARMA – Dependence on Success of its CF Pipeline = Risk

Date: 2015-07

Vertex Pharma’s (VRTX) stock has moved up ~30% in this year mostly based on the positive expectation building on Lumacaftor/KALYDECO (CFTR corrector/ CFTR potentiator, PhIII, homozygous del508 mutation Cystic fibrosis/CF), after it received breakthrough therapy designation from the FDA. VRTX entered into three non-exclusive agreements to conduct PhII IFN-free PoC studies of VX-135 in combination with BMY’s daclatasvir (NS5A Inhivitor, PhII), JNJ/MVIR’s Simeprevir (PI, PhII) and with GSK’s GSK2336805, (NS5A inhibitor, PhII) but the competition are way ahead and after risk reward analysis of the pipeline, there remains limited…..For more detail, please read our report released on 9th March, 2013 on Vertex titled “Dependence on Success of its CF Pipeline = Risk!”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample